ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Background Radioimmunotherapy has a promising antitumor effect in hepatocellular carcinoma (HCC), depending on the regulatory effect of radiotherapy on tumor immune microenvironment. Ionizing radiation (IR)-induced DNA damage repair (DDR) pathway activation leads to the inhibition of immune microenvironment, thus impairing the antitumor effect of radioimmunotherapy. However, it is unclear whether inhibition of the DDR pathway can enhance the effect of radioimmunotherapy. In this study, we aim to explore the role of DDR inhibitor AZD6738 on the combination of radiotherapy and immune checkpoint inhibitors (ICIs) in HCC. Methods C57BL/6 mouse subcutaneous tumor model was used to evaluate the ability of different treatment regimens in tumor growth control and tumor recurrence inhibition. Effects of each treatment regimen on the alterations of immunophenotypes including the quantification, activation, proliferating ability, exhaustion marker expression, and memory status were assessed by flow cytometry. Results AZD6738 further increased radiotherapy-stimulated CD8 + T cell infiltration and activation and reverted the immunosuppressive effect of radiation on the number of Tregs in mice xenografts. Moreover, compared with radioimmunotherapy (radiotherapy plus anti-PD-L1 (Programmed death ligand 1)), the addition of AZD6738 boosted the infiltration, increased cell proliferation, enhanced interferon (IFN)-γ production ability of TIL (tumor-infiltrating lymphocyte) CD8 + T cells, and caused a decreasing trend in the number of TIL Tregs and exhausted T cells in mice xenografts. Thus, the tumor immune microenvironment was significantly improved. Meanwhile, triple therapy (AZD6738 plus radiotherapy plus anti-PD-L1) also induced a better immunophenotype than radioimmunotherapy in mice spleens. As a consequence, triple therapy displayed greater benefit in antitumor efficacy and mice survival than radioimmunotherapy. Mechanism study revealed that the synergistic antitumor effect of AZD6738 with radioimmunotherapy relied on the activation of cyclic GMP–AMP synthase /stimulator of interferon genes (cGAS/STING) signaling pathway. Furthermore, triple therapy led to stronger immunologic memory and lasting antitumor immunity than radioimmunotherapy, thus preventing tumor recurrence in mouse models. Conclusions Our findings indicate that AZD6738 might be a potential synergistic treatment for radioimmunotherapy to control the proliferation of HCC cells, prolong survival, and prevent tumor recurrence in patients with HCC by improving the immune microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, ATR inhibitors appear to offset the ability of RT to drive PD-L1 upregulation (Vendetti et al., 2018) and hence synergize with RT and ICIs in the control of mouse hepatocellular carcinomas established in immunocompetent hosts (Sheng et al., 2020).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Sheng et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,853
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 1×
“Based on preliminary translational observations, our work raised the possibility that AZD6738 might be a potential synergistic modality for radioimmunotherapy in HCC. Remark-edly, this study provides a basis for future clinical human studies into the treatment of HCC.”
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652 · cited 1×
“In summary, compared with radioimmunotherapy, triple therapy can further reduce the coexpression of CD8 + T cell exhaustion markers in mice xenograft tumors and spleens.”
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280 · cited 1×
“7 8 There are increasing substantial preclinical studies showing that radiotherapy combined with ICIs improve the control rate and reduce the recurrence rate of multiple types of cancers, including HCC. 9 Therefore, it appears that the combination of radiotherapy and ICIs may become a promising…”
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y.-X. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,105
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Blackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062
Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737 · cited 1×
“11 14 However, other than simulative effect, radiation also has suppressive effect on the tumor environment.”
Cited by
Items 101–200 of 241
Quan, Z., Gao, Y., Sun, B., Guo, Y., Jin, Z., Hao, N., Jiang, D., Zheng, C., Li, X., & Chen, Q. (2025) · Biomarker Research · doi:10.1186/s40364-025-00820-z · Cited by 14
Chen, K., Zhu, S.-G., He, J.-W., & Duan, X.-P. (2022) · Neoplasma · doi:10.4149/neo_2022_211230n1853 · Cited by 15
“1262 [19] SHENG H, HUANG Y, XIAO Y, ZHU Z, SHEN M et al.”
BackgroundMethodReal-World Use of Immunotherapy for Hepatocellular Carcinoma
Sara, A., Ruff, S. M., Noonan, A. M., & Pawlik, T. M. (2023) · Pragmatic and Observational Research · doi:10.2147/por.s397972 · Cited by 18
“Currently, this effect of combination therapy has been demonstrated in pre-clinical studies with mouse HCC models and is also being investigated in early phase trials.(60,61) Zhu et al treated twenty HCC patients with neoadjuvant TACE and a PD-1 inhibitor as a bridge to surgery.”
BackgroundShannon, A. H., Manne, A., Diaz, D. A., & Pawlik, T. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1193762 · Cited by 13
“No severe adverse events were noted (97).”
Jia, H., Wei, P., Zhou, S., Hu, Y., Zhang, C., Liang, L., Li, B., Gan, Z., Xia, Y., Jiang, H., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01603-x · Cited by 13
“Radiation therapy induces DNA damage in tumor cells, which promotes the release of dsDNA and activates the cGAS/STING pathway, leading to lymphocyte infiltration in tumor tissues [9].”
BackgroundLiu, C., Tang, L., Yang, W., Gu, Y., Xu, W., Liang, Z., & Jiang, J. (2024) · Oncology Reports · doi:10.3892/or.2024.8848 · Cited by 13
Qin, S., Cheng, X., Zhou, Z., Zhang, X., Chen, J., Xu, P., Wu, T. H., & Hu, Y. (2025) · ACS Nano · doi:10.1021/acsnano.5c04279 · Cited by 13
DNA damage repair and cancer immunotherapy
Xiang, Z., Liu, H., & Hu, Y. (2023) · Genome Instability & Disease · doi:10.1007/s42764-023-00098-1 · Cited by 13
Locally advanced non-small cell lung cancer: current issues and recent trends
Alaswad, M. (2023) · Reports of Practical Oncology & Radiotherapy · doi:10.5603/rpor.a2023.0019 · Cited by 15
Wang, H., Li, Z., Ou, S., Song, Y., Luo, K., Guan, Z., Zhao, L., Huang, R., & Yu, S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.884839 · Cited by 13
“…can cause variation in tumor biology, thus affecting the efficacy of multiple therapies (Casey et al., 2015; Wu and Dai, 2017), including chemotherapy (Hanoteau et al., 2019), radiotherapy (Yin et al., 2019; Sheng et al., 2020), and immune checkpoint therapy (Lei et al., 2020; Sheng et al., 2020).”
BackgroundSelf-citationZhang, X., Zhang, C., Zhang, Z., & Zhang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1628573 · Cited by 13
Cytosolic DNA accumulation promotes breast cancer immunogenicity via a STING-independent pathway
Zhang, J., Dai, H., Huo, L., Burks, J. K., McGrail, D. J., & Lin, S. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007560 · Cited by 13
Huang, A., Guo, F., Yu, Z., Liu, P., Dong, S., Zhang, Y., Kong, Y., Kong, X., Li, T., Luo, Y., et al. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c19769 · Cited by 12
Fauvre, A., Ursino, C., Garambois, V., Culerier, E., Milazzo, L.-A., Vié, N., Jeanson, L., Marchive, C., Andrade, A. F., Combès, E., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010791 · Cited by 11
Fan, Y., Dong, Z., Wu, Y., & Wen, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1692365 · Cited by 12
Insights into anti-tumor immunity via the polyomavirus shared across human Merkel cell carcinomas
Jani, S., Church, C. D., & Nghiem, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172913 · Cited by 12
Lu, Y., Feng, N., Du, Y., & Yu, R. (2022) · Nanomaterials · doi:10.3390/nano12162832 · Cited by 12
“The TME not only provides a protective “ecological niche” for tumor cells to thrive, progress, and metastasize but also affects the responses to therapy [18,19].”
BackgroundLiu, Z., Yuan, J., Zeng, Q., Wu, Z., & Han, J. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167481 · Cited by 10
A medicinal chemistry perspective on ATR: Current status and future directions
Li, K., Sun, X., Liu, S., Liu, Y., Feng, X., & Zhang, G. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117834 · Cited by 10
Zhang, X., Wen, J., Zhang, G., Fan, W., Tan, J., Liu, H., & Li, J. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101600 · Cited by 10
Shao, C., Yan, X., Pang, S., Nian, D., Ren, L., Li, H., & Sun, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111781 · Cited by 10
Self-citationYang, J., & Chen, R. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104773 · Cited by 9
Overcoming radioresistance in prostate cancer by targeting DNA damage repair
Matos, A. C., Lima, M. L. S. D. O., Miranda‐Gonçalves, V., Indraccolo, S., Jerónimo, C., & Saraiva, L. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218183 · Cited by 10
Comprehensive analysis of CPSF4-related alternative splice genes in hepatocellular carcinoma
Yuemaierabola, A., Guo, J., Sun, L., Yeerkenbieke, B., Liu, F., Ye, D., Zhai, X., Guo, W., & Cao, Y. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05178-z · Cited by 9
“Advanced hepatocellular carcinoma patients have been demonstrated to benefit from immune checkpoint inhibitors (ICIs) (Sheng et al. 2020).”
BackgroundGao, X., Ren, X., Wang, F., Ren, X., Liu, M., Cui, G., & Liu, X. (2024) · Scientific Reports · doi:10.1038/s41598-024-59877-9 · Cited by 10
Daphnegiravone D from Daphne giraldii induces cell death by targeting ATR in Hep3B cells
Shang, X., Yu, X., Yao, G., & Song, S. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104802 · Cited by 9
Hintelmann, K., Petersen, C., & Borgmann, K. (2022) · Cancers · doi:10.3390/cancers15010211 · Cited by 9
“Thus, the tumor immune microenvironment was significantly improved [145].”
BackgroundLai, Y., Han, L., Chen, M., Lin, X., Wu, L., Zhao, Y., Lin, F., & Lin, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1115202 · Cited by 10
“Ionizing radiation-induced activation of DDR is the major cause contributing to the interference of immune microenvironment, thus reducing the anti-tumor effect of radioimmunotherapy (52).”
BackgroundVasilopoulos, S. N., Tremi, I., Kotta‐Loizou, I., Gkikoudi, A., Tsitsilonis, O., Havaki, S., & Georgakilas, A. G. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48010067 · Cited by 8
“Triple treatment with AZD6738, radiation, and anti—programmed death-ligand 1 (anti-PD-L1) activated the cGAS-STING signalling pathway and demonstrated promising therapeutic potential in mouse models—it significantly inhibited tumor growth, prolonged survival, and delayed tumor recurrence [97].”
AZD6738 promotes the tumor suppressive effects of trifluridine in colorectal cancer cells
Harata, S., Suzuki, T., Takahashi, H., Hirokawa, T., Kato, A., Watanabe, K., Yanagita, T., Ushigome, H., Shiga, K., Ogawa, R., et al. (2023) · Oncology Reports · doi:10.3892/or.2023.8489 · Cited by 9
Zhang, Q., Chen, Y., Bai, X., & Liang, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.590058 · Cited by 8
“A DDR inhibitor AZD6738 and radiotherapy combined with anti-PD-L1 antibodies could perform better tumor growth inhibition and recurrence prevention by boosting CD8 T cell infiltration and activation in tumor microenvironment in a mouse model (93).”
BackgroundExploring the DNA damage response pathway for synthetic lethality
Xu, X., Nowsheen, S., & Deng, M. (2022) · Genome Instability & Disease · doi:10.1007/s42764-022-00087-w · Cited by 9
“AZD6738 has been demonstrated to enhance the anti-tumor activity of chemo-radiotherapy, Olaparib and ICI treatment (Nakamura et al., 2021; Sheng, 2020).”
BackgroundImpact of DNA Damage Response—Targeted Therapies on the Immune Response to Tumours
Lutfi, N., Galindo-Campos, M. A., & Yélamos, J. (2021) · Cancers · doi:10.3390/cancers13236008 · Cited by 8
“Treatment with different ATRi results in innate immune and T cell activation mediated by cGAS-STING pathway in various mouse models of cancer, including those for prostate cancer [60], hepatocellular carcinoma [34] and ovarian cancer [61].”
BackgroundATR inhibition sensitizes liposarcoma to doxorubicin by increasing DNA damage.
Cui, J., Dean, D. C., Hornicek, F. J., Pollock, R. E., Hoffman, R. M., & Duan, Z. (2022) · PubMed · Cited by 8
Chen, L., Lin, J., Wen, Y., Guo, Z., Lan, B., Xiong, J., Chen, C., & Chen, Y. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s497295 · Cited by 7
Self-citationDeppas, J. J., Kiesel, B. F., Guo, J., Rigatti, L. H., Latoche, J. D., Green, A. R., Knizner, P., Clump, D. A., Pandya, P., Vendetti, F. P., et al. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117375 · Cited by 7
Tumor irradiation induced immunogenic response: the impact of DNA damage induction and misrepair
Liu, Q., Shi, X., Tayier, N., & Ma, L. (2025) · Radiation Oncology · doi:10.1186/s13014-025-02711-x · Cited by 8
“In hepatocellular carcinoma, ATR inhibition combined with radiotherapy synergistically improved anti-PD-L1 responses via cGAS-STING activation [93].”
He, X., Sun, Z., Sun, J., Chen, Y., Luo, Y., Wang, Z., Linghu, D., Song, M., & Cao, C. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.173562 · Cited by 7
Self-citationStringhetta, G. R., Mass, E. B., Gomes, I. N. F., Peixoto, M., Tejada, A. H., Susucchi, L., Bezerra, A. J. A., Resende, P. V. S., Vendrusculo, V., Reis, R. M., et al. (2025) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2025.100250 · Cited by 8
Isono, M., Okubo, K., Asano, T., & Sato, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266476 · Cited by 7
A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors
Li, Y., Fu, W., Geng, Z., Song, Y. H., Yang, X., He, T., Wu, J., & Wang, B. (2022) · PeerJ · doi:10.7717/peerj.14432 · Cited by 7
“It may cause an immune system blockage, resulting in a long-term anti-cancer response (Palmieri & Carlino, 2018; Deng et al., 2021; Sheng et al., 2020; Xu et al., 2020).”
BackgroundRecent advances in small molecule ATR kinase inhibitors as anticancer agents
Singh, G., Sharma, R., Gautam, V., Dhingra, A. K., Hsu, S., & Nepali, K. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2620367 · Cited by 6
Targeting ATR in Cancer Medicine
Salguero, C., Valladolid, C., Robinson, H. M. R., Smith, G. C. M., & Yap, T. A. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-30065-3_14 · Cited by 6
Liu, Q.-J., Zhang, J.-C., Wang, Y., Zou, M., Zhou, W., Lu, Y., Feng, X.-C., & Liu, H. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i7.107815 · Cited by 6
Mariampillai, A. E., Hauge, S., Øynebråten, I., Rødland, G. E., Corthay, A., & Syljuåsen, R. G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.981332 · Cited by 6
Chen, J. L., Pan, C.-K., Lin, L.-C., Huang, Y., Huang, T.-H., Yang, S., Kuo, S., & Lin, Y. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03864-6 · Cited by 6
“ATRi treatment altered the activation status of tumor-infiltrating CD8 + T cells, resulting in downregulated expression of PD-1, LAG3, and Tim3, along with an increase in IFN-γ-secreting CD8 + T cells, thereby enhancing the cytotoxic activity of these cells [15, 23].”
BackgroundMethodSelf-citationHodson, D., Mistry, H. B., Yates, J. W. T., Farrington, P. M., Staniszewska, A. D., Guzzetti, S., Davies, M., Aarons, L. J., & Ogungbenro, K. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001572 · Cited by 6
Hodson, D., Mistry, H. B., Guzzetti, S., Davies, M., Staniszewska, A. D., Farrington, P. M., Cadogan, E. B., Yates, J. W. T., Aarons, L. J., & Ogungbenro, K. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13026 · Cited by 6
“Sheng et al. 32 were able to show significant efficacy of RT/ATRi/ICI due to improved immunogenicity and tumor control after three doses of 6Gy external beam radiation in the hepatocellular carcinoma syngeneic model— Hepa 1– 6.”
MethodATR promotes mTORC1 activity via de novo cholesterol synthesis
Tangudu, N. K., Grumet, A. N., Fang, R., Buj, R., Cole, A. R., Uboveja, A., Amalric, A., Yang, B., Huang, Z., Happe, C., et al. (2025) · EMBO Reports · doi:10.1038/s44319-025-00451-3 · Cited by 5
“…ciency have been shown to potentiate immunotherapy in preclinical models (Cantini et al, 2021; Gao et al, 2024; Kansal et al, 2023; Liao et al, 2025; Mao et al, 2022; Takada et al, 2022), phenocopying ATR inhibitors (Hardaker et al, 2024; Ngoi et al, 2022; Sheng et al, 2020; Taniguchi et al, 2024).”
Li, R.-P., Wu, G., Fang, X.-D., Yang, W., Zhang, H., Yue, H., Zheng, Y., Wang, Y., & Zhou, Y.-N. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s508709 · Cited by 5
“Subsequently, according to the method described by Sheng H et al 20 for establishing an HCC tumor model, we successfully created a hepatoma model by subcutaneously implanting 5 × 10^6 hepa1-6 cells into the right posterior flank of each mouse (n=12).”
InfluentialNan, H., Yang, P., Wang, L., Li, W., Liu, Y., Huang, F., Xu, F., Shi, M., & Bai, Y. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s552797 · Cited by 5
“29 31–33 Thus, the SII—which integrates neutrophil, platelet, and lymphocyte counts—offers a composite index reflecting both inflammation and immune status.”
Mavroeidi, D., Papanikolaou, C. A., Deligianni, E., Malamos, P., Stamou, P., Syrigos, K. N., & Souliotis, V. L. (2026) · Cancers · doi:10.3390/cancers18050820 · Cited by 5
Deciphering cGAS-STING signaling: implications for tumor immunity and hepatocellular carcinoma
Chandramoorthy, H. C. K., Saleh, R. O., Altalbawy, F. M. A., Mohammed, J. S., Ganesan, S., Kundlas, M., Premkumar, J., Ray, S., Mustafa, Y. F., & Abbas, J. K. K. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04240-6 · Cited by 6
“DNA damage activates cGAS in cells via two main pathways (Sheng et al. 2020).”
Mini-review: the distinct roles of STING signaling in tumor immunity—recent progress
Wang, S., Li, T., Sun, H., Chen, D., Xu, H., & Hao, J. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiad051 · Cited by 5
Ye, L., Tong, X., Pan, K., Shi, X., Xu, B., Yao, X., Zhuo, L., Su, F., Tang, S., Jiang, Z., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1351929 · Cited by 5
Liu, S., Jia, L., Quan, B., Rong, G., Li, M., Xie, R., Cai, Y., Bi, Y., & Han, S. (2022) · Disease Markers · doi:10.1155/2022/7745315 · Cited by 5
“Furthermore, poor prognosis of the CCDC45 overexpression group was associated with an overregulation of immune-related suppressor genes and chemokine receptors [42].”
BackgroundExploring SPK98 for the Selective Sensitization of ATM- or P53-Deficient Cancer Cells
Priya, B., Dubey, G., & Kirubakaran, S. (2023) · ACS Omega · doi:10.1021/acsomega.2c07356 · Cited by 5
I kappa B kinase interacting protein as a promising biomarker in pan-cancer: A multi-omics analysis
Bi, C., Wang, Z., Xiao, Y., Zhao, Y., Guo, R., Xiong, L., Ji, Z., Li, Y., Li, Q., & Qin, C. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1138137 · Cited by 4
“A block in the immune system is removed by immune checkpoint blocking medication, which also prompts a long-lasting anticancer response (Schaub et al., 2018; Deng et al., 2020; Sheng et al., 2020; Xu et al., 2020).”
BackgroundSelf-citationTargeting mitotic regulators in cancer as a strategy to enhance immune recognition
Gregorczyk, M., & Parkes, E. E. (2023) · DNA repair · doi:10.1016/j.dnarep.2023.103583 · Cited by 4
Chen, Y., Tao, T., Wu, Y., Wang, W., & Liu, S. (2024) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2023.175 · Cited by 4
Li, J., Cheng, X., Huang, D., & Cui, R. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117598 · Cited by 4
Establishment of image‐guided radiotherapy of orthotopic hepatocellular carcinoma mouse model
Zhou, K., Jiang, Y., Feng, S., Mo, W., Nie, J., Cao, J., & Jiao, Y. (2023) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12335 · Cited by 4
Eskiler, G. G., Halis, H., Hamarat, K. F., Derlioglu, R. R., Uğurlu, B. T., & Haciefendi, A. (2024) · International Journal of Radiation Biology · doi:10.1080/09553002.2024.2316606 · Cited by 4
“As expected, RT induces G2/M arrest in different types of cancer (Sheng et al. 2020; Faulhaber et al. 2021).”
BackgroundNon-linear IV pharmacokinetics of the ATR inhibitor berzosertib (M6620) in mice
Deppas, J. J., Kiesel, B. F., Guo, J., Parise, R. A., Clump, D. A., D’Argenio, D. Z., Bakkenist, C. J., & Beumer, J. H. (2024) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-024-04675-3 · Cited by 4
“Small molecule ATR inhibitors (ATRi) show promising antitumor activity in multiple preclinical models when combined with DNA-damaging agents, such as IR and immune checkpoint inhibitors (ICI) [7–9].”
Wu, G., Liu, Y., Fan, H., Rao, M., Zhang, J., & Zhang, J. (2025) · Discover Oncology · doi:10.1007/s12672-025-02171-5 · Cited by 4
“…immunogenic cell death, induce tumor antigen release, act as an immune adjuvant [17], increase the expression of tumor-infiltrating CD4 + and CD8 + T lymphocytes, reverse immunosuppressive effects, enhance the production of interferon-γ, and enhance the anti-tumor activity of the TME [18, 19].”
Feng, Y., Wang, S., Zhang, J., Liu, C., Zhang, L., & Liu, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-06376-0 · Cited by 4
Zhou, K., Jiang, Y., Feng, S., Wang, T.-Y., Wang, L., Cao, J., & Jiao, Y. (2022) · Radiation Medicine and Protection · doi:10.1016/j.radmp.2022.07.005 · Cited by 4
Song, H., He, N., Xu, C., Wang, Y., Du, L., Liu, Y., Wang, Q., Ji, K., Wang, J., Zhang, M., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-1165183/v1 · Cited by 4
Self-citationNie, A.-Y., Xiao, Z.-H., Deng, J., Li, N., Hao, L., Li, S.-H., & Hu, X.-Y. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i2.98556 · Cited by 3
“By administering the DNA damage response inhibitor AZD6738 to HCC mice, Sheng et al [136] found that cGAS, phosphorylated STING (p-STING), and p-TBK1 levels were elevated.”
Zhou, S., & Zeng, Q. (2025) · Organic Chemistry Frontiers · doi:10.1039/d5qo00681c · Cited by 3
Combination strategies with STING agonists: Current advances and future directions
Sun, K., Fu, X., Man, Y., Liu, F., Qu, Z., Ou, Y., Cheng, W., Bian, J., Li, Z., Wang, J., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178286 · Cited by 3
Self-citationSolomon, A. D., Vats, H. K., Chowdhary, S., Kanoujiya, S. N., Prakash, A., Sultana, H., Mohanty, S., Day, B. W., & Pant, T. (2026) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2026.071632 · Cited by 5
Lopez, J. S., Harrington, K. J., Im, S., Lee, K., Postel-Vinay, S. C., Thomas, J. S., Lukashchuk, N., Willis, S. E., Irurzun‐Arana, I., Webb, B., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03408-y · Cited by 3
The DNA damage response and cancer immunotherapy
Sheng, H., & Li, G. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00958-4 · Cited by 4
Self-citationXu, T., Xu, M., Xu, Y., Cai, X., Brenner, M. J., Twigg, J. A., Fei, Z., & Chen, C. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-2345 · Cited by 3
Wang, W., Liu, Y., Chen, D., Pang, J., Lai, C., Gu, M., Zhai, M., Yu, Q., Wang, Y., Bao, X., et al. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102598 · Cited by 3
Zhang, Y., Liu, H., Wang, K., Zheng, J., Luan, H., & Xin, M. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s473390 · Cited by 3
Hodson, D., Mistry, H. B., Yates, J. W. T., Guzzetti, S., Davies, M., Aarons, L. J., & Ogungbenro, K. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2024.106774 · Cited by 3
Zhong, L., Peng, W., Sun, J., Luo, Y., Sheng, H., Wu, Y. L., Zhou, T., Zhou, C., & Cao, C. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s480691 · Cited by 2
“17 This study conducted a comprehensive analysis of the alterations in tumor-infiltrating immune cells at various time points following radiation therapy to determine the optimal timing for intervention with ICIs.”
Self-citationYang, X., Gao, D.-D., Zhang, H., Sun, W.-J., Zhu, S., Zhang, X.-P., Wang, H.-Q., Zhang, S., & Wang, H. (2025) · Technology in Cancer Research & Treatment · doi:10.1177/15330338251406931 · Cited by 2
Self-citationTargeting Galectin-9 to overcome immunosuppression and potentiate ATR inhibitor therapy
Liu, D., Liu, B., Yang, R., Song, J., Chen, Q., Liu, Z., Xiong, S., Shi, S., Hung, M., & Sun, L. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218283 · Cited by 2
Dai, J., Ma, L., Han, X., Li, X., Han, L., & Wang, W. (2026) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2026.10041 · Cited by 2
“102).”
PARP7 inhibition and a STING agonist potentiate radiation-induced immunogenicity in glioblastoma
Lippert, L., Kleinwächter, A., Ohradanova‐Repic, A., Horvat, F., Appel, L.-M., Walch, L., Bragato, N., Wimmer, J., Wopfner, H., Rohrer, A. M., et al. (2026) · OncoImmunology · doi:10.1080/2162402x.2026.2656053 · Cited by 2
Kiesel, B. F., Parise, R. A., Krishnamurthy, A., Gore, S. D., & Beumer, J. H. (2022) · Biomedical Chromatography · doi:10.1002/bmc.5455 · Cited by 2
Bai, Y., He, J., Ma, Y., He, L., Li, M., & Wu, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1180722 · Cited by 2
“DDR inhibitors can reverse the immunosuppressive state of HCC and inhibit tumor progression, providing a potential therapeutic strategy (22).”
BackgroundNanomedicine Approach to Immunotherapy of Hepatocellular Carcinoma
Ni, H., Xue, J., Wang, F., Sun, X., & Niu, M. (2021) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2021.3055 · Cited by 4
He, K., Selek, U., Barsoumian, H. B., Sezen, D., Ning, M. S., Puebla‐Osorio, N., Schoenhals, J. E., Chen, D., Leuschner, C., Cortez, M. A., et al. (2022) · Medical radiology · doi:10.1007/174_2022_315 · Cited by 2
Role of Calponin 2 as a Tumor Inhibitor in Esophageal Cancer
Gan, M., Xia, Y., Pan, Y., Yu, Q., Guo, Y., Feng, Y., & Zheng, J. (2023) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.1137 · Cited by 1
Tang, M., Xue, S., Yuan, R.-S., Li, H.-Y., Li, X., Jing, Y.-M., Zhang, Y., Shen, H., Wang, Z., Zhou, L., et al. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i5.2091 · Cited by 1
Therapeutic Potential of Chick Early Amniotic Fluid in Mitigating Ionizing-Radiation-Induced Damage
Zhang, K., Yang, H., Wu, Y., Zhao, Y., Xin, W., Han, D., Sun, N., & Ye, C. (2025) · Biomedicines · doi:10.3390/biomedicines13051253 · Cited by 1
“Central immune organs, such as the thymus [33,34], and peripheral immune organs, such as the spleen [35,36], experience rapid damage when exposed to acute and severe IR, often resulting in swift and progressive atrophy.”
Pannhausen, J., Chughtai, A. A., Yüce, C.-L., Melzer, M. K., Ma, Y., Seillier, L., van der Vorst, E. P. C., Andrieux, G., Wirtz, J., Leypold, S., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03603-4 · Cited by 2
“Ceralasertib has also been investigated as a radio-sensitizer in preclinical models of melanoma [33], colorectal [33, 34], hepatocellular [35], and lung carcinoma [34, 36], as well as in SCC of head and neck, ovary, and oral cavity [34].”
Targeting ATR in Cancer therapy: A drug discovery perspective
Lai, Y., Zhao, W., Wang, Y., & Zhang, L. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109707 · Cited by 1
Yan, X., Dong, X., Yao, L., Guo, M., & Wang, N. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156425 · Cited by 1
Zhou, K., Yuan, W., & Zhang, F. (2026) · Scientific Reports · doi:10.1038/s41598-026-47257-4 · Cited by 1
“The mice were then injected at the left liver with 100 µL of 5 × 10 6 Hepa 1–6 cells (SNL-118, Sunncell, Wuhan, China) 30 or Hepa 1–6 cells mixed with CAFs, CAFs sh−NC , or CAFs sh−CLCF1 (ratio 1:4) 31 .”
Xia, T., Li, Y., Zhao, X., & Song, Z. (2026) · Pakistan Journal of Pharmaceutical Sciences · doi:10.36721/pjps.2026.39.7.192.1 · Cited by 1
Zhang, H., Lu, Y., Xiong, H., Shi, L., Xu, H., Jia, Y., Zhao, J., & Sheng, H. (2026) · Nature Communications · doi:10.1038/s41467-026-75415-9 · Cited by 1
Self-citationPeng, X., Wu, H., Zhang, B., Xu, C. S., & Lang, J. (2023) · Current Cancer Drug Targets · doi:10.2174/1568009623666230817101843 · Cited by 1
Simões, J. L. B., Braga, G. D. C., Coiado, J. V., Scaramussa, A. B., Rodrigues, A. P. B., & Bagatini, M. D. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116388 · Cited by 1
Pang, J., Yu, Y., Li, L., Zhao, Y., Li, J.-D., Li, L., Wei, X.-X., Gao, R., Wen, R., He, Y., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1596120 · Cited by 1
Li, K., Qin, Y., & Ye, L. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006648 · Cited by 1
Metadata
- Authors
- Sheng, H., Huang, Y., Xiao, Y., Zhu, Z., Shen, M., Zhou, P., Guo, Z., Wang, J., Wang, H., Dai, W., Zhang, W., Sun, J., & Cao, C.
- Affiliations
- Nanfang Hospital (CN)
- Department of Radiation Oncology, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China
- Department of Stomatology, No 2 Hospital of Baoding, Baoding, Hebei, China
- Corresponding author
- Cao, Chuanhui
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2020-05
- Volume
- 8
- Issue
- 1
- Pages
- e000340
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC7254123
- OpenAlex
- W3029836467
- Cited by
- 228
- References
- 40
- Citations by year
- 2026: 24 · 2025: 40 · 2024: 36 · 2023: 42 · 2022: 49 · 2021: 31 · 2020: 5
- FWCI
- 11.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81702390, 81903133)
- Guangzhou Science and Technology Program key projects (201906010087)
- Natural Science Foundation of Guangdong Province (2017A030310105, 2018A030313398)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- AZD6738, hepatocellular carcinoma, radioimmunotherapy, DNA repair inhibition, tumor immune microenvironment, immune checkpoint inhibitors, PD-L1 inhibitors, radiotherapy, cGAS-STING pathway, CD8+ T cells, regulatory T cells, T cell exhaustion, tumor-infiltrating lymphocytes, immunological memory, combination therapy, tumor recurrence
- MeSH terms
- Immune Checkpoint Inhibitors, Animals, Disease Models, Animal, Drug Synergism, Female, Carcinoma, Hepatocellular, Humans, Indoles, Liver Neoplasms, Morpholines, Pyrimidines, Sulfonamides, Sulfoxides, Lymphocytes, Tumor-Infiltrating, Radioimmunotherapy, CD8-Positive T-Lymphocytes, Drug Resistance, Neoplasm, Cell Line, Tumor, Protein Kinase Inhibitors, Mice, Tumor Microenvironment, Chemoradiotherapy, B7-H1 Antigen, Ataxia Telangiectasia Mutated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.